CaseScenario2:Compliance,Inc.
Compliance, Inc. (CI) conducts clinical human and animal trials for the pharmaceutical
and biotechnology industries. Revenues are split evenly between early and late drug
development services and the firm is a leader in the laboratory technologies needed for
such testing. One of CI’s internal quality managers, Sharon Kline, has approached the
CEO with a new business proposal. She would like to see the firm take one of its
in-house software programs and develop it as a leadingÂedge commercial product for
three specific target markets€medical care providers, payers of medical care, like
insurance companies, and suppliers to medical care providers, like pharmaceutical
companies. The features of the software are easy to use and include electronic
distribution, data harvesting, and robust reporting capabilities. With this software
Sharon believes that medical care providers will be able to collect data to market to and
negotiate contracts with payers or employers, profile performance of individual
physicians or practice sites, identify best clinical practices, generate reports that satisfy
regulatory or accreditation requirements for provider sites, and supply professional
societies with data for influencing payer and government policies. Another target
market, insurance companies and other medical services payers, will be able to use the
software to profile performance of individual physicians or practice sites, identify best
clinical practices, generate reports that satisfy regulatory or accreditation requirements,
and collect data to market to and negotiate contracts with employers. Finally, the
software will allow suppliers to medical care providers to assess how products perform
compared to competitor products, assess outcomes in real-world compared to clinical
trial settings, obtain information on provider-specific practice patterns, determine
whether products are being used correctly, get “face- time” with physicians and HMOs,
obtain information on product switching behavior, offer providers a value-added
service, and meet FDA post-marketing surveillance requirements. CI has never
launched such a product before and, even if successful, software is a very different
product than the clinical trials services it provides now. The CEO must determine how
to build and manage this new business for CI.
Where does it appear that autonomous strategic behavior ends and induced strategic
behavior begins in the software situation at CI?